New Thermo Scientific Vanquish Core HPLC system for pharmaceutical analysis at Quinta-Analytica

Our Pharmaceutical Analysis Department has now expanded its HPLC fleet with a new Thermo Scientific Vanquish Core Binary HPLC System equipped with a variable wavelength detector (VWD). With around 50 HPLC systems available across our laboratories, the new instrument further strengthens the capacity supporting our day-to-day analytical operations.

For our clients, a broad HPLC fleet means more than simply additional instrument capacity. It provides greater scheduling flexibility, faster allocation of analytical work and greater operational reliability, helping us accommodate routine workloads as well as changing project requirements more efficiently.

The new Vanquish Core will primarily support routine HPLC methods with UV detection, with a particular focus on the analysis of small-molecule pharmaceuticals.

Thermo Scientific instrumentation has long been an important part of our instrument portfolio, particularly in the area of LC-MS systems, where we value high sample throughput and straightforward method transfer between systems.

Our Pharmaceutical Analysis Department supports pharmaceutical companies across a broad range of analytical activities, including analytical method validation and transfer, quality control, stability studies and release testing. HPLC remains one of the key analytical techniques used across many of these workflows.


Would you like to know more? Let us know.

Additional News

  • 7 August 2026

    Quinta-Analytica at CPHI Milan 2026 – Meet Us at Conscio Group Stand 6N25

    Meet Quinta-Analytica at CPHI Milan 2026 as part of the Conscio Group team at Stand 6N25. Discuss your clinical, bioanalytical and analytical projects with our experts and arrange a meeting in advance.

  • 15 July 2026

    Quinta-Analytica Awarded the EcoVadis Gold Medal

    Quinta-Analytica has been awarded the EcoVadis Gold Medal after achieving an overall sustainability score of 84 out of 100. The result represents a substantial increase from 68 points in the previous assessment and places the company in the 97th percentile globally.

  • 16 April 2026

    Expanding Beyond FDA & EMA: Strengthening Our Global Regulatory Footprint with GCC

    Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.